接受司库奇尤单抗或阿达木单抗治疗的银屑病关节炎患者的附着点炎:EXCEED 研究的事后分析
EXCEED 研究事后分析评估司库奇尤单抗或阿达木单抗治疗 52 周对银屑病关节炎附着点炎的疗效,基线 LEI 附着点炎 498/851 例(58.5%)、SPARCC 632/853 例(74.1%);两种药物在第 24 周和第 52 周附着点炎完全缓解比例及缓解时间相似,附着点炎缓解与第 52 周生活质量改善相关。
要点
- 基线时 LEI 评估附着点炎占 58.5%,SPARCC 评估占 74.1%。
- 第 52 周 LEI 缓解率司库奇尤单抗 60.7% vs 阿达木单抗 55.3%。
- 两种药物附着点炎缓解时间及单个附着点改善相似。
核心结论
- 司库奇尤单抗与阿达木单抗在附着点炎缓解方面疗效相似,包括缓解时间。
- 司库奇尤单抗抑制 IL-17 与 TNF-α 抑制对临床附着点炎的减轻作用相似。
研究设计与样本
- EXCEED 研究的事后分析,患者按标签接受司库奇尤单抗 300 mg 或阿达木单抗 40 mg 治疗 52 周。
- 依据基线 LEI 和 SPARCC 是否存在附着点炎对患者分组。
- 疗效评估采用无应答者填补法分析附着点炎缓解(LEI/SPARCC=0),Kaplan-Meier 分析缓解时间,其他结局采用实际观察数据。
主要发现
- 基线时 LEI 评估附着点炎 498/851 例(58.5%),SPARCC 评估 632/853 例(74.1%)。
- 有基线附着点炎的患者总体疾病活动度更高。
- 第 24 周 LEI/SPARCC 缓解率:司库奇尤单抗 49.6%/45.8%,阿达木单抗 43.6%/43.5%。
- 第 52 周 LEI/SPARCC 缓解率:司库奇尤单抗 60.7%/53.2%,阿达木单抗 55.3%/51.4%。
- 两种药物的平均附着点炎缓解时间相当,单个附着点改善相似,第 52 周附着点炎缓解与生活质量改善相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate enthesitis treatment response, including time to resolution and data from multiple enthesitis instruments, in patients with PsA treated with secukinumab or adalimumab for 52 weeks. METHODS: In this post hoc analysis of the EXCEED study, patients receiving secukinumab 300 mg or adalimumab 40 mg per the label were grouped by presence or absence of baseline enthesitis based on the Leeds Enthesitis Index (LEI) and the Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC). Efficacy was assessed according to several enthesitis-related instruments using non-responder imputation for the achievement of enthesitis resolution (LEI/SPARCC = 0), Kaplan-Meier analysis for time to resolution, and as-observed data for other outcomes. RESULTS: Enthesitis was present at baseline in 498 of 851 patients (58.5%) as assessed by LEI and in 632 of 853 patients (74.1%) as assessed by SPARCC. Patients with baseline enthesitis generally presented with greater disease activity. Similar proportions of patients receiving secukinumab or adalimumab achieved resolution of LEI and SPARCC at weeks 24 (secukinumab: LEI/SPARCC, 49.6%/45.8%; adalimumab: LEI/SPARCC, 43.6%/43.5%) and 52 (secukinumab: LEI/SPARCC, 60.7%/53.2%; adalimumab: LEI/SPARCC, 55.3%/51.4%), with comparable mean time to enthesitis resolution. Improvements were similar for both drugs at individual enthesitis sites. Resolution of enthesitis with secukinumab or adalimumab was associated with improvements in quality of life at week 52. CONCLUSION: Secukinumab and adalimumab showed similar efficacy, including time to resolution, with respect to resolution of enthesitis. Inhibition of IL-17 with secukinumab reduced clinical enthesitis similarly to TNF-α inhibition. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02745080.
引用
- Kaeley GS, Schett G, Conaghan PG, et al. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study. Rheumatology (Oxford). 2024. PMID: 37097894. doi:10.1093/rheumatology/kead181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。